Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.

Evidence supporting an early origin of prostate cancer is growing. We demonstrated previously that brief exposure of neonatal rats to estradiol or bisphenol A elevated their risk of developing precancerous lesions in the prostate upon androgen-supported treatment with estradiol as adults. Epigenetic reprogramming may be a mechanism underlying this inductive event in early life, because we observed overexpression of phosphodiesterase 4D variant 4 (Pde4d4) through induction of hypomethylation of its promoter. This epigenetic mark was invisible in early life (postnatal d 10), becoming apparent only after sexual maturation. Here, we asked whether other estrogen-reprogrammable epigenetic marks have similar or different patterns in gene methylation changes throughout life. We found that hypomethylation of the promoter of nucleosome binding protein-1 (Nsbp1), unlike Pde4d4, is an early and permanent epigenetic mark of neonatal exposure to estradiol/bisphenol A that persists throughout life, unaffected by events during adulthood. In contrast, hippocalcin-like 1 (Hpcal1) is a highly plastic epigenetic mark whose hypermethylation depends on both type of early-life exposure and adult-life events. Four of the eight genes involved in DNA methylation/demethylation showed early and persistent overexpression that was not a function of DNA methylation at their promoters, including genes encoding de novo DNA methyltransferases (Dnmt3a/b) and methyl-CpG binding domain proteins (Mbd2/4) that have demethylating activities. Their lifelong aberrant expression implicates them in early-life reprogramming and prostate carcinogenesis during adulthood. We speculate that the distinctly different fate of early-life epigenetic marks during adulthood reflects the complex nature of lifelong editing of early-life epigenetic reprogramming.

[1]  G. Song,et al.  The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells , 2011, Tumor Biology.

[2]  M. Bustin,et al.  Distinct Properties of Human HMGN5 Reveal a Rapidly Evolving but Functionally Conserved Nucleosome Binding Protein , 2011, Molecular and Cellular Biology.

[3]  Juxiang Chen,et al.  HMGN5: a potential oncogene in gliomas , 2011, Journal of Neuro-Oncology.

[4]  D. Merkle,et al.  Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. , 2011, Cellular signalling.

[5]  Shuk-Mei Ho,et al.  Epigenetics meets endocrinology. , 2011, Journal of molecular endocrinology.

[6]  Danny Reinberg,et al.  Molecular Signals of Epigenetic States , 2010, Science.

[7]  L. Doherty,et al.  Bisphenol‐A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  N. Jiang,et al.  Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. , 2010, Asian journal of andrology.

[9]  H. Shibuya,et al.  DNA demethylation in hormone-induced transcriptional derepression , 2009, Nature.

[10]  J. McNally,et al.  The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. , 2009, Molecular cell.

[11]  H. Grönberg,et al.  Birth Characteristics and Risk of Prostate Cancer: the Contribution of Genetic Factors , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[12]  D. Largaespada,et al.  Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. , 2009, Cancer research.

[13]  N. Rifai,et al.  Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  M. Medvedovic,et al.  Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. , 2008, Endocrinology.

[15]  Archana Dhasarathy,et al.  The MBD protein family-reading an epigenetic mark? , 2008, Mutation research.

[16]  G. Prins.  Endocrine disruptors and prostate cancer risk. , 2008, Endocrine-related cancer.

[17]  A. Bellacosa,et al.  VILIP-1 Downregulation in Non-Small Cell Lung Carcinomas: Mechanisms and Prediction of Survival , 2008, PloS one.

[18]  M. Szyf,et al.  On the mechanism of demethylation of 5-methylcytosine in DNA. , 2008, Bioorganic & medicinal chemistry letters.

[19]  D. Gudbjartsson,et al.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes , 2007, Nature Genetics.

[20]  S. Ho,et al.  Epigenetic reprogramming and imprinting in origins of disease , 2007, Reviews in Endocrine and Metabolic Disorders.

[21]  O. Brawley,et al.  Prostate cancer and race. , 2007, Current problems in cancer.

[22]  Peter McCarron,et al.  A Prospective Investigation of Height and Prostate Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[23]  Y. Kaneda,et al.  Dnmt3a2 targets endogenous Dnmt3L to ES cell chromatin and induces regional DNA methylation , 2006, Genes to cells : devoted to molecular & cellular mechanisms.

[24]  A. Klein-Szanto,et al.  Correlation of visinin‐like‐protein‐1 expression with clinicopathological features in squamous cell carcinoma of the esophagus , 2006, Molecular carcinogenesis.

[25]  G. Song,et al.  [Expression of nucleosomal binding protein 1 in normal prostate benign prostate hyperplasia, and prostate cancer and significance thereof]. , 2006, Zhonghua yi xue za zhi.

[26]  C. Stief,et al.  Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. , 2006, European urology.

[27]  A. Bird,et al.  DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. , 2005, Molecular cell.

[28]  K. Braunewell.  The darker side of Ca2+ signaling by neuronal Ca2+-sensor proteins: from Alzheimer's disease to cancer. , 2005, Trends in pharmacological sciences.

[29]  Michael K. Skinner,et al.  Epigenetic Transgenerational Actions of Endocrine Disruptors and Male Fertility , 2005, Science.

[30]  J. Chernoff,et al.  Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells , 2005, Oncogene.

[31]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[32]  Peter Gluckman,et al.  Developmental plasticity and human health , 2004, Nature.

[33]  E. Crawford,et al.  Epidemiology of prostate cancer. , 2003, Urology.

[34]  J. McLachlan,et al.  Neonatal diethylstilbestrol exposure induces persistent elevation of c‐fos expression and hypomethylation in its exon‐4 in mouse uterus , 2003, Molecular carcinogenesis.

[35]  E. Jablonka,et al.  The Changing Concept of Epigenetics , 2002, Annals of the New York Academy of Sciences.

[36]  W. Reik,et al.  Epigenetic Reprogramming in Mammalian Development , 2001, Science.

[37]  M. Bustin.  Chromatin unfolding and activation by HMGN(*) chromosomal proteins. , 2001, Trends in biochemical sciences.

[38]  R. Newbold,et al.  Uterine adenocarcinoma in mice treated neonatally with genistein. , 2001, Cancer research.

[39]  E. Avvedimento,et al.  cAMP signaling selectively influences Ras effectors pathways , 2001, Oncogene.

[40]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[41]  D. Landsman,et al.  NBP-45, a Novel Nucleosomal Binding Protein with a Tissue-specific and Developmentally Regulated Expression* , 2000, The Journal of Biological Chemistry.

[42]  H. Adami,et al.  Duration of gestation and prostate cancer risk in offspring. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  J. Kaprio,et al.  Genetic predisposition, environment and cancer incidence: A nationwide twin study in Finland, 1976–1995 , 1999, International journal of cancer.

[44]  M. Szyf,et al.  A mammalian protein with specific demethylase activity for mCpG DNA , 1999, Nature.

[45]  J. McLachlan,et al.  Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. , 1997, Cancer research.

[46]  M. Bustin,et al.  The HMG-14/-17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates. , 1995, Seminars in cell biology.

[47]  B. Katzenellenbogen,et al.  Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Rosner,et al.  Estradiol causes the rapid accumulation of cAMP in human prostate. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  B. Henderson,et al.  Do diet and androgens alter prostate cancer risk via a common etiologic pathway? , 1994, Journal of the National Cancer Institute.

[50]  J. McLachlan,et al.  Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. , 1990, Cancer research.

[51]  L. Chung,et al.  Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. , 1989, Endocrinology.

[52]  G. Prins.  Differential regulation of androgen receptors in the separate rat prostate lobes: androgen independent expression in the lateral lobe. , 1989, Journal of steroid biochemistry.

[53]  A. Bird,et al.  Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs , 1989, Cell.

[54]  G. Prins,et al.  Effect of Estradiol on the Rat Prostate in the Presence and Absence of Testosterone and Pituitary , 1981 .

[55]  D PRICE,et al.  COMPARATIVE ASPECTS OF DEVELOPMENT AND STRUCTURE IN THE PROSTATE. , 1963, National Cancer Institute monograph.

[56]  G. Prins,et al.  Serum bisphenol A pharmacokinetics and prostate neoplastic responses following oral and subcutaneous exposures in neonatal Sprague-Dawley rats. , 2011, Reproductive toxicology.

[57]  L. Mahadevan,et al.  Signalling to chromatin through post-translational modifications of HMGN. , 2010, Biochimica et biophysica acta.

[58]  G. Gerlitz.  HMGNs, DNA repair and cancer. , 2010, Biochimica et biophysica acta.

[59]  M. Bustin,et al.  HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. , 2010, Biochimica et biophysica acta.

[60]  Shuk-Mei Ho,et al.  4 Epigenetically Regulates Phosphodiesterase Type 4 Variant Increases Susceptibility to Prostate Carcinogenesis and Developmental Exposure to Estradiol and Bisphenol A , 2006 .

[61]  A. Ekbom,et al.  Growing evidence that several human cancers may originate in utero. , 1998, Seminars in cancer biology.

[62]  I. Leav,et al.  Testosterone-mediated increase in 5 alpha-dihydrotestosterone content, nuclear androgen receptor levels, and cell division in an androgen-independent prostate carcinoma of Noble rats. , 1988, Cancer research.